https://www.jonesday.com/en/practices/experience/2019/01/shanghai-junshi-biosciences-completes-450-million
Jones Day acted as Hong Kong and U.S. counsel for Shanghai Junshi Biosciences Co., Ltd. in connection with its over $450 million initial public offering on The...
shanghaijunshibiosciencescompletesmillion
https://www.jonesday.com/en/practices/experience/2023/05/junshi-grants-exclusive-rights-to-dr-reddys-for-toripalimab-cancer-treatment
Jones Day represented Shanghai Junshi Biosciences Co., Ltd. ("Junshi") in its grant of exclusive rights related to the development and commercialization of...
exclusive rightsdr reddyjunshigrantstoripalimab
https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.
toripalimabshanghaijunshibiosciencesadenocarcinoma